Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.75 |
| ▸ | PI4KA | P42356 | 3/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.67 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
| ▸ | ADCY5 | O95622 | 9/20 | 0.64 |
| ▸ | AHCY | P23526 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12321001 | 1.00 | ADORA2A (0.75) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30315880 | 1.00 | ADORA2A (0.75) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4351091 | 1.00 | ADORA2A (0.75) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5188585 | 1.00 | ADORA2A (0.75) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9470633 | 0.90 | ADORA2A (0.71) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28984637 | 0.86 | ADORA2A (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL27459374 | 0.84 | ADORA2A (0.77) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9685991 | 0.83 | ADORA2A (0.50) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10474172 | 0.82 | ADCY5 (0.74) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9309056 | 0.82 | ADORA2A (0.69) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2022-12-29 | — | — | US | disclosed |
| CN-110003172-B | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | 同步制药公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-107674071-B | Carbazole-containing sulfonamides as cryptochrome modulators | 同步制药公司 | 2021-12-31 | — | — | CN | disclosed |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | Synchronicity (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2855458-B1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170261520-A1 | Markers Associated With Arteriovascular Events And Methods Of Use Thereof | TRUE HEALTH IP LLC (US) | 2017-09-14 | — | — | US | disclosed |
| US-9689880-B2 | Markers associated with arteriovascular events and methods of use thereof | TRUE HEALTH IP LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-20140147850-A1 | DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF | TETHYS BIOSCIENCE, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
| US-8409816-B2 | Diabetes-related biomarkers and methods of use thereof | TETHYS BIOSCIENCE, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120179484-A1 | DIABETES-RELATED BIOMARKERS AND METHODS OF USE THEREOF | TETHYS BIOSCIENCE, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110008805-A1 | Markers Associate with Arteriovascular Events and Methods of Use Thereof | TETHYS BIOSCIENCE, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7790735-B2 | Methanocarba cycloalkyl nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790735-B2 | Methanocarba cycloalkyl nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100168210-A1 | T-Cell Cytokine-Inducing Surface Molecules and Methods of Use | EDWARDS III CARL KEITH | 2010-07-01 | — | — | US | disclosed |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | CRY1, CRY2, CRYAB | ADORA2A 1409/4885PI4KA 4750/4885PI4K2B 4604/4885 |
| US-20220411399-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | ADORA2A 1496/4885PI4KA 4286/4885PI4K2B 4316/4885 |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | CRY1, CRY2, CRYAB | ADORA2A 1396/4885PI4KA 4731/4885PI4K2B 4582/4885 |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADORA2A, PDE4A, PDE4D | ADORA2A 1/4885PI4KA 778/4885PI4K2B 847/4885 |
| US-10005759-B2 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | CRY1, CRY2, HCCS | ADORA2A 1496/4885PI4KA 4286/4885PI4K2B 4316/4885 |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | BCL6, BCL6B, BCL3 | ADORA2A 9/4885PI4KA 1500/4885PI4K2B 1286/4885 |
| US-20100168210-A1 | T-Cell Cytokine-Inducing Surface Molecules and Methods of Use | CD14, CD4, IL15RA | ADORA2A 2635/4885PI4KA 3244/4885PI4K2B 3670/4885 |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | ADORA2A 1396/4885PI4KA 4731/4885PI4K2B 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.